Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Translational Medicine.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

  Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

  Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

  Your Personal Message

  CAPTCHA

  This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

  Send Message
• Download Powerpoint
• Print
• Alerts

  Please log in to add an alert for this article.

  Log In with your AAAS ID

  Sign In to Email Alerts with your Email Address

  Email

  Log in
• Citation tools

  Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

  By Janelle C. Waite, Bei Wang, Lauric Haber, Aynur Hermann, Erica Ullman, Xuan Ye, Drew Dudgeon, Rabih Slim, Dharani K. Ajithdoss, Stephen J. Godin, Ilyssa Ramos, Qi Wu, Erin Oswald, Patrick Poon, Jacquelynn Golubov, Devon Grote, Jennifer Stella, Arpita Pawashe, Jennifer Finney, Evan Herlihy, Hassan Ahmed, Vishal Kamat, Amanda Dorvilliers, Elizabeth Navarro, Jenny Xiao, Julie Kim, Shao Ning Yang, Jacqueline Warsaw, Clarissa Lett, Lauren Canova, Teresa Schulenburg, Randi Foster, Pamela Krueger, Elena Garnova, Ashique Rafique, Robert Babb, Gang Chen, Nicole Stokes Oristian, Chia-Jen Siao, Christopher Daly, Cagan Gurer, Joel Martin, Lynn Macdonald, Douglas MacDonald, William Poueymirou, Eric Smith, Israel Lowy, Gavin Thurston, William Olson, John C. Lin, Matthew A. Sleeman, George D. Yancopoulos, Andrew J. Murphy, Dimitris Skokos

  Science Translational Medicine24 Jun 2020

  Antibodies cross-linking the CD28 costimulatory pathway and a target antigen on tumors potentiate the effects of checkpoint immunotherapy.

  • Supplementary Materials

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

  By Janelle C. Waite, Bei Wang, Lauric Haber, Aynur Hermann, Erica Ullman, Xuan Ye, Drew Dudgeon, Rabih Slim, Dharani K. Ajithdoss, Stephen J. Godin, Ilyssa Ramos, Qi Wu, Erin Oswald, Patrick Poon, Jacquelynn Golubov, Devon Grote, Jennifer Stella, Arpita Pawashe, Jennifer Finney, Evan Herlihy, Hassan Ahmed, Vishal Kamat, Amanda Dorvilliers, Elizabeth Navarro, Jenny Xiao, Julie Kim, Shao Ning Yang, Jacqueline Warsaw, Clarissa Lett, Lauren Canova, Teresa Schulenburg, Randi Foster, Pamela Krueger, Elena Garnova, Ashique Rafique, Robert Babb, Gang Chen, Nicole Stokes Oristian, Chia-Jen Siao, Christopher Daly, Cagan Gurer, Joel Martin, Lynn Macdonald, Douglas MacDonald, William Poueymirou, Eric Smith, Israel Lowy, Gavin Thurston, William Olson, John C. Lin, Matthew A. Sleeman, George D. Yancopoulos, Andrew J. Murphy, Dimitris Skokos

  Science Translational Medicine24 Jun 2020

  Antibodies cross-linking the CD28 costimulatory pathway and a target antigen on tumors potentiate the effects of checkpoint immunotherapy.

  • Supplementary Materials

  Share This Article: Copy